REPLIMUNE GROUP INC (REPL)
Sector: Health Care
2026 Annual Meeting Analysis
REPLIMUNE GROUP INC · Meeting: September 15, 2026
Directors FOR
null
Directors AGAINST
null
Say on Pay
AGAINST
Auditor
FOR
Say on Pay
✗ AGAINSTCEO
Sushil Patel
Total Comp
$3,697,661
Prior Support
N/A
Replimune's stock has lost 74.4% over the past three years while the XBI — SPDR S&P Biotech ETF gained 76.6% over the same period, a gap of 151 percentage points that massively exceeds the 20-percentage-point threshold that triggers a pay-for-performance concern. Despite this severe underperformance, the CEO's total reported compensation jumped sharply from approximately $3.7 million in fiscal year 2025 to approximately $5.8 million in fiscal year 2026, driven by large increases in stock awards and option grants, and the CEO still received 75% of his target cash bonus. The structure of the incentive plan — awarding substantial above-benchmark variable pay (large equity grants plus meaningful bonuses) while shareholders have experienced devastating losses relative to biotech peers — represents a clear failure of pay-for-performance alignment under the voting policy.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
8 yrs
Audit Fees
$1,173,784
Non-Audit Fees
$321,809
Non-audit fees (tax fees of $319,684 plus other fees of $2,125 = $321,809) represent approximately 27% of audit fees ($1,173,784), well below the 50% threshold that would raise independence concerns; PwC has served since 2018 (approximately 8 years), far short of the 25-year tenure trigger; no material restatements were identified; and PwC is a Big 4 firm appropriate for a company of this size and complexity.
Stockholder Proposals
1 proposal submitted by shareholders
Proposal 3
Approval of an Amendment to the Third Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock from 150,000,000 Shares to 300,000,000 Shares
As of March 31, 2026, Replimune had only about 30.3 million shares available for future issuance out of 150 million authorized — roughly 20% of its current authorization — after accounting for shares outstanding, outstanding stock options, unvested stock awards, equity plan reserves, and pre-funded warrants. For a pre-commercial biotech company that needs to raise capital to fund clinical development and that has an active at-the-market offering program, having an adequate reserve of authorized shares is a legitimate and necessary operational requirement. Doubling the authorized share count from 150 million to 300 million is consistent with common practice for clinical-stage biotechs that must preserve flexibility to pursue equity offerings, strategic partnerships, and equity compensation without seeking stockholder approval on a transaction-by-transaction basis; while there is potential dilution, the business rationale is clear and the board has stated no specific takeover-defensive intent.
Overall Assessment
This annual meeting contains three proposals: auditor ratification (FOR — PwC fees are clean with a 27% non-audit ratio and only 8 years of tenure), Say on Pay (AGAINST — CEO compensation surged to $5.8M in FY2026 while the stock underperformed the XBI — SPDR S&P Biotech ETF by 151 percentage points over three years, a fundamental pay-for-performance failure), and a board-proposed charter amendment to double authorized shares from 150M to 300M (FOR — justified by the company's pre-commercial biotech status, limited remaining authorized share headroom of only 20%, and legitimate need for capital-raising flexibility). No director elections are on the ballot at this meeting as the two Class II directors whose terms expire (Pucci and Peeples-Dyer) were not nominated for reelection, leaving those seats vacant.